Development of the diagnostic system of bone marrow failure with a minor population of PNH-phenotype cells
使用少量 PNH 表型细胞开发骨髓衰竭诊断系统
基本信息
- 批准号:22591032
- 负责人:
- 金额:$ 2.83万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2010
- 资助国家:日本
- 起止时间:2010 至 2012
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Although detection of PNH-type cells is useful as a marker for immune pathophysiology of bone marrow failure, it is often difficult when the percentage of PNH-type cells is less than 0.1%. We established an objective method of quantifying PNH-type with mathematical analysis of the fluorescent intensity of GPI-anchored proteindots on the flow cytometry dotgram, but the method was difficult to generalize. The use of fluorescent labeled aerolysin (FLARE) instead of monoclonal antibodies greatly improved the accuracy of detecting PNH-type cells. However, some patients without increased PNH-type cells respond to immunosuppressive therapy. To identify a better marker for immune pathophysiology of bone marrow failure, we examined a correlation of plasma thrombopoietin (TPO) levels with pathophysiology of bone marrow failure. Bone marrow failure patients showing TPO levels>320 pg/ml proved to have benign diseases with immune pathophysiology and virtually included all patients with increased PNH-type cells. The measurement of plasma TPO levels is therefore useful for diagnosing pathophysiology of bone marrow failure.
尽管检测 PNH 型细胞可作为骨髓衰竭免疫病理生理学的标志物,但当 PNH 型细胞的百分比低于 0.1% 时,检测往往很困难。我们通过对流式细胞术点图上 GPI 锚定蛋白点的荧光强度进行数学分析,建立了一种定量 PNH 型的客观方法,但该方法很难推广。使用荧光标记气溶素(FLARE)代替单克隆抗体大大提高了检测PNH型细胞的准确性。然而,一些 PNH 型细胞未增加的患者对免疫抑制治疗有反应。为了确定骨髓衰竭免疫病理生理学的更好标记,我们检查了血浆血小板生成素(TPO)水平与骨髓衰竭病理生理学的相关性。 TPO 水平>320 pg/ml 的骨髓衰竭患者被证明患有具有免疫病理生理学的良性疾病,并且实际上包括所有 PNH 型细胞增加的患者。因此,血浆 TPO 水平的测量对于诊断骨髓衰竭的病理生理学很有用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YAMAZAKI Hirohito其他文献
YAMAZAKI Hirohito的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YAMAZAKI Hirohito', 18)}}的其他基金
Establishment of a method to predict the effects of immunosuppressive therapy for aplastic anemia
再生障碍性贫血免疫抑制治疗效果预测方法的建立
- 批准号:
18591050 - 财政年份:2006
- 资助金额:
$ 2.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
The role of CD109 and TGF-beta for the preferential commitment of PIGA mutant HSPCs in immune-mediated bone marrow failure.
CD109 和 TGF-β 在免疫介导的骨髓衰竭中优先承诺 PIGA 突变型 HSPC 的作用。
- 批准号:
15K09496 - 财政年份:2015
- 资助金额:
$ 2.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of auto-antigens which trigger the development of immune-mediated bone marrow failure
鉴定引发免疫介导的骨髓衰竭发展的自身抗原
- 批准号:
21390291 - 财政年份:2009
- 资助金额:
$ 2.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Establishment of a method to predict the effects of immunosuppressive therapy for aplastic anemia
再生障碍性贫血免疫抑制治疗效果预测方法的建立
- 批准号:
18591050 - 财政年份:2006
- 资助金额:
$ 2.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNH赤血球各型のDAFおよびAchEの局在と臨床病態との関連性についての検討
各型PNH红细胞中DAF和AchE定位与临床病理关系的探讨
- 批准号:
63770906 - 财政年份:1988
- 资助金额:
$ 2.83万 - 项目类别:
Grant-in-Aid for Encouragement of Young Scientists (A)